Overview

* Fulgent reports Q2 2025 total revenus of $81.8 million, beating analyst expectations

* Adjusted EPS for Q2 beats consensus, despite GAAP loss of $19 mln

* Co repurchased 130,000 shares, reflecting confidence in business strategy

Outlook

* Fulgent expects 2025 core revenue of approximately $320 mln

* Company projects 2025 GAAP loss of $2.10 per share

* Fulgent anticipates 2025 non-GAAP loss of $0.35 per share

* Company expects cash and investments of $770 mln by year-end

Result Drivers

* LABORATORY SERVICES - Growth attributed to progress in Laboratory Services business

* THERAPEUTIC DEVELOPMENT - Advancements in clinical trials for Therapeutic Development business

* RAISED GUIDANCE - Increased full-year core revenue guidance to $320 mln, reflecting positive momentum

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $81.80 $76.20

Revenue mln mln (3

Analysts

)

Q2 Core $81.70

Revenue mln

Q2 Beat $0.07 -$0.18

Adjusted (3

EPS Analysts

)

Q2 Beat -$3 mln -$7.60

Adjusted mln (2

EBITDA Analysts

)

Q2 Miss -$21.52 -$5.75

Pretax mln mln (2

Profit Analysts

)

Q2 Gross $34.44

Profit mln

Q2 $54.15

Operatin mln

g

Expenses

Q2 -$19.71

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy."

* Wall Street's median 12-month price target for Fulgent Genetics Inc ( FLGT ) is $23.00, about 25.3% above its July 31 closing price of $17.18

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)